Skip to Main content Skip to Navigation
Journal articles

Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)

David Tougeron 1, * Maxime Hentzien 2 Barbara Seitz-Polski 3 Firouze Bani-Sadr 2 Jean Bourhis 4 Michel Ducreux 5, 6 Sébastien Gaujoux 7 Philippe Gorphe 5, 8 Boris Guiu 9 Khê Hoang-Xuan 7 Florence Huguet 10 Thierry Lecomte 11, 12, 13 Astrid Lièvre 14 Christophe Louvet 15 Léon Maggiori 16 Laura Mansi 17 Pascale Mariani 18 Pierre Michel 19 Amélie Servettaz 2 Juliette Thariat 20 Virgine Westeel 17 Thomas Aparicio 16 Jean-Yves Blay 21 Olivier Bouché 2
Abstract : The impacts of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on cancer care are multiple, entailing a high risk of death from coronavirus disease 2019 (COVID-19) in patients with cancer treated by chemotherapy. SARS-CoV-2 vaccines represent an opportunity to decrease the rate of severe COVID-19 cases in patients with cancer and also to restore normal cancer care. Patients with cancer to be targeted for vaccination are difficult to define owing to the limited contribution of these patients in the phase III trials testing the different vaccines. It seems appropriate to vaccinate not only patients with cancer with ongoing treatment or with a treatment having been completed less than 3 years ago but also household and close contacts. High-risk patients with cancer who are candidates for priority access to vaccination are those treated by chemotherapy. The very high-priority population includes patients with curative treatment and palliative first- or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large volume of lung, lymph node and/or haematopoietic tissue. When possible, vaccination should be carried out before cancer treatment begins. SARS-CoV-2 vaccination can be performed during chemotherapy while avoiding periods of neutropenia and lymphopenia. For organisational reasons, vaccination should be performed in cancer care centres with messenger RNA vaccines (or non-replicating adenoviral vaccines in non-immunocompromised patients). Considering the current state of knowledge, the benefit-risk ratio strongly favours SARS-CoV-2 vaccination of all patients with cancer. To obtain more data concerning the safety and effectiveness of vaccines, it is necessary to implement cohorts of vaccinated patients with cancer.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03225104
Contributor : Laurent Jonchère <>
Submitted on : Friday, June 11, 2021 - 2:28:40 PM
Last modification on : Tuesday, July 13, 2021 - 3:29:32 AM
Long-term archiving on: : Sunday, September 12, 2021 - 7:47:56 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-10-01

Please log in to resquest access to the document

Identifiers

Citation

David Tougeron, Maxime Hentzien, Barbara Seitz-Polski, Firouze Bani-Sadr, Jean Bourhis, et al.. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). European Journal of Cancer, Elsevier, 2021, 150, pp.232-239. ⟨10.1016/j.ejca.2021.03.030⟩. ⟨hal-03225104⟩

Share

Metrics

Record views

118